TCRR - TCR2 Therapeutics share slumps 11% announces response for Phase 1/2 Trial of TC-210

TCR2 Therapeutics (TCRR) announces positive interim data from the ongoing Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors.TC-210 induced tumor regression in all of the first eight patients and ovarian cancer patient achieved confirmed RECIST partial response.Overall response rate was 50% in patients infused with TC-210 and lymphodepletion with continued manageable toxicity profile and Phase 1 trial amended to accelerate treatment.Company will host conference call Monday, December 14 starting at 8:00am E.T. live webcast available.“Although the focus of any Phase 1 trial is safety, the consistency in tumor regression and RECIST responses we have observed with gavo-cel as a single agent supports our belief in the advantages of TRuC-T cells over other cell therapies and the potential for a fundamentally new approach in the treatment of solid tumors. The HLA independence of our technology allows us to treat a broad population of patients with mesothelin surface expression while

For further details see:

TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210